Omnicell (OMCL) AI Stock Analysis

• Market Cap: $1.36B
• Dividend Yield: N/A
• Average Volume (3M): 447.87K
• Price to Earnings (P/E): 65.2
• Beta (1Y): 0.34
• Revenue Growth: 3.00%
• EPS Growth: N/A
• Country: US
• Employees: 3,620
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.26
• Shares Outstanding: 46,843,605
• 10 Day Avg. Volume: 527,141
• 30 Day Avg. Volume: 447,870
• PEG Ratio: 0.91
• Price to Book (P/B): 1.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 11.66
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: 0.64
• Enterprise Value/Gross Profit: 5.46
• Enterprise Value/Ebitda: 4.83
• 1Y Price Target: $40.60
• Price Target Upside: 37.07% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 70 Outperform
• Price Target: $32.00 ▲(8.04%Upside)

Omnicell's overall score is driven by solid financial health and positive corporate actions, such as the stock buyback plan. However, high valuation and technical weakness weigh down the score, alongside challenges highlighted in the earnings call, such as the tariff impact.

Positive Factors

Manufacturing Strategy

Management indicated Omnicell is one year into a three-year plan to move much manufacturing to the U.S., which could reduce future tariff impacts.

Product Revenue Growth

Omnicell is tracking to an estimated $69MM in total robotic revenue for 2025, suggesting a potential $5MM year-over-year improvement.

Tariff Conditions

A potential post-pause tariff rate of 55% implies a favorable scenario for Omnicell, leading to significant savings.

Negative Factors

CapEx Outlook

The broader CapEx outlook weakened for the second consecutive quarter as uncertainty around tariffs and legislation appear to be impacting spend.

Product Revenue Uncertainty

Limited visibility into components of product revenue growth creates uncertainty near-term.

Tariff Volatility

The ever-changing tariff backdrop, particularly with China, has led to two guidance revisions and significant stock price volatility.

Omnicell Business Overview & Revenue Model

Company Description

Omnicell, Inc. (OMCL) is a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies. The company operates within the healthcare and technology sectors, focusing on the development and delivery of automated medication dispensing systems, central pharmacy automation solutions, and medication adherence tools. Omnicell's products and services enable healthcare providers to enhance medication safety, increase operational efficiency, and improve patient outcomes.

How the Company Makes Money

Omnicell generates revenue through the sale and leasing of its medication management and automation systems to hospitals, healthcare systems, and pharmacies. Key revenue streams include the direct sale of hardware products, such as automated dispensing cabinets, and software solutions for medication management. Additionally, Omnicell offers service contracts for maintenance and support, which provide a recurring revenue stream. The company also benefits from partnerships with healthcare providers and pharmaceutical companies, facilitating the integration of its solutions into broader healthcare management systems. These partnerships, along with ongoing advancements in healthcare technology, contribute significantly to Omnicell's earnings.

Omnicell Financial Statement Overview

Summary

Omnicell's financial statements reflect a stable revenue growth and strong gross profit margin, although net profit margins are low. The balance sheet is robust with high equity ratios and low leverage, while cash flows are solid, showing strong cash generation. However, profitability improvement is needed.

Income Statement

Omnicell's income statement reveals stable revenue with a modest TTM growth of approximately 2.12% from the previous year. Gross profit margin stands strong at 43.08%, indicating efficient cost management. However, net profit margin is low at 1.86%, reflecting challenges in controlling operating costs. The EBIT margin at 0.93% and EBITDA margin at 4.89% highlight subdued operational profitability, though improvements are visible compared to prior losses.

Balance Sheet

The balance sheet is robust with a high equity ratio of 58.43%, showcasing financial stability. The debt-to-equity ratio of 0.30 indicates low leverage, reducing financial risks. Return on equity is moderate at 1.68%, pointing to potential for improved profitability. Overall, Omnicell maintains a strong financial position with ample equity backing.

Cash Flow

Cash flows are strong, with TTM free cash flow at $116.55 million and a positive free cash flow to net income ratio of 5.50. Operating cash flow to net income is notably high at 7.73, reflecting excellent cash generation from operations. Although free cash flow growth shows a decline compared to the previous year, the company sustains healthy cash reserves and operational liquidity.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.11B	1.15B	1.30B	1.13B	892.21M
Gross Profit	471.00M	499.93M	588.99M	554.65M	413.29M
EBITDA	90.09M	60.69M	96.85M	174.44M	107.12M
Net Income	12.53M	-20.37M	5.65M	77.85M	32.19M
Balance Sheet
Total Assets	2.12B	2.23B	2.21B	2.14B	1.82B
Cash, Cash Equivalents and Short-Term Investments	381.68M	467.97M	330.36M	349.05M	485.93M
Total Debt	382.55M	614.09M	616.74M	528.06M	516.10M
Total Liabilities	877.65M	1.04B	1.08B	995.81M	857.00M
Stockholders Equity	1.24B	1.19B	1.13B	1.15B	967.50M
Cash Flow
Free Cash Flow	151.26M	126.08M	17.04M	173.47M	131.00M
Operating Cash Flow	187.72M	181.09M	77.78M	231.81M	185.87M
Investing Cash Flow	-52.79M	-55.02M	-58.67M	-412.50M	-279.87M
Financing Cash Flow	-235.58M	23.42M	-20.95M	47.36M	456.27M

Omnicell Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 29.62
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OMCL, the sentiment is Neutral. The current price of 29.62 is above the 20-day moving average (MA) of 28.68, above the 50-day MA of 29.13, and below the 200-day MA of 37.14, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 56.90 is Neutral, neither overbought nor oversold. The STOCH value of 87.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OMCL.

Omnicell Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OMCL	70 Outperform	$1.36B	65.17	1.73%	―	3.00%	―
PINC	68 Neutral	$1.74B	36.99	6.05%	3.98%	-17.69%	-10.24%
PHR	68 Neutral	$1.61B	―	-15.97%	―	16.29%	66.01%
HSTM	64 Neutral	$817.77M	42.87	5.40%	0.44%	3.36%	7.51%
SDGR	58 Neutral	$1.64B	―	-43.33%	―	22.29%	-32.89%
Sector *	52 Neutral	$7.58B	0.48	-62.71%	2.36%	15.33%	0.41%
TDOC	51 Neutral	$1.44B	―	-14.18%	―	-2.57%	79.86%

Omnicell Corporate Events

Omnicell CFO Nchacha Etta to Step Down

Omnicell, Inc. announced that its Chief Financial Officer, Nchacha Etta, will step down from his role effective September 15, 2025, or until a successor is named. The company has entered into a separation agreement with Mr. Etta, extending his separation date to November 15, 2025, and outlining terms for his continued service and benefits, including a severance payment, bonus eligibility, and additional vesting credit for equity awards.

The most recent analyst rating on (OMCL) stock is a Buy with a $61.00 price target. To see the full list of analyst forecasts on Omnicell stock, see the OMCL Stock Forecast page.

Omnicell Stockholders Approve Key Proposals at Annual Meeting

On May 21, 2025, Omnicell, Inc. held its Annual Meeting where stockholders voted on several key proposals. Three directors, Edward P. Bousa, Mary Garrett, and Bruce E. Scott, were elected to the Board until 2028. The stockholders also approved executive officer compensation and an amendment to the 2009 Equity Incentive Plan, which includes an additional 1,750,000 shares for issuance. Additionally, Deloitte & Touche LLP was ratified as the independent accounting firm for 2025.

The most recent analyst rating on (OMCL) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Omnicell stock, see the OMCL Stock Forecast page.

Omnicell Updates 2025 Guidance and Stock Buyback Plan

On May 22, 2025, Omnicell announced an update to its second quarter and full-year 2025 guidance, reflecting improved profitability due to reduced tariff rates on imports from China. The company also introduced a new $75 million stock repurchase program, indicating confidence in its financial health and commitment to delivering innovative medication management solutions.

The most recent analyst rating on (OMCL) stock is a Buy with a $53.00 price target. To see the full list of analyst forecasts on Omnicell stock, see the OMCL Stock Forecast page.